Full year 2025 financial guidance excludes any potential share repurchase or additional M&A activity. CEO Dr. Steve Cutler commented, "ICON continues to navigate dynamic clinical development ...
ICON plc, (NASDAQ: ICLR), a world-leading clinical research organization powered by healthcare intelligence, today announced its financial guidance for the year ending December 31, 2025.
In a ”Worker Adjustment & Retraining Notification Notices” (WARN) report issued by the Texas Workforce Commission, it states ...
Truist Financial analyst Jailendra Singh assigned a Buy rating to Icon (ICLR – Research Report) today and set a price target of $284.00. The company’s shares closed yesterday at $203.26.